Zevra Therapeutics: Business Model, SWOT Analysis, and Competitors 2026

Zevra Therapeutics, Inc. stands as a leading company in Healthcare. Generating $84.39 million in annual revenue (growing 605.4% year-over-year) and carrying a market capitalization of $494.86 million, the company has cemented its position as a foundational player in the global Biotechnology landscape. Under the leadership of its leadership team, Zevra Therapeutics, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Zevra Therapeutics, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Zevra Therapeutics, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Zevra Therapeutics, Inc.'s position in the Biotechnology market today.

What You Will Learn

1. How Zevra Therapeutics, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Zevra Therapeutics, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Zevra Therapeutics, Inc.'s main competitors are and how the company compares on key financial metrics
4. Zevra Therapeutics, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Zevra Therapeutics, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $84.39 million annual revenue (TTM), +605.4% YoY
• Market Cap: $494.86 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 80.7%, operating margin 15.9%, net margin 41.9%
• Free Cash Flow: $-30.06 million
• Return on Equity: 34.8% — strong
• Employees: 59 worldwide

Who Owns Zevra Therapeutics, Inc.?

Zevra Therapeutics, Inc. is publicly traded on the NMS under the ticker symbol ZVRA. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Zevra Therapeutics, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Zevra Therapeutics, Inc. has approximately 0.06 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $8.79 per share as of early 2026.

Zevra Therapeutics, Inc.'s Mission Statement

Zevra Therapeutics, Inc.'s strategic mission is aligned with its core business activities in the Biotechnology sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Zevra Therapeutics, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Zevra Therapeutics, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Zevra Therapeutics, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Zevra Therapeutics, Inc. Make Money?

As of 2026, Zevra Therapeutics, Inc. generates $84.39 million in annual revenue (growing 605.4% year-over-year), with a 80.7% gross margin and 15.9% operating margin. Market capitalization stands at $494.86 million. Here is how the company generates its revenue:

Zevra Therapeutics Inc. operates within the biotechnology sector, focusing primarily on the development and commercialization of therapeutics for rare diseases. Its business model is multifaceted and revolves around the following key components:

1. Research and Development (R&D)

At the heart of Zevra's business model is its commitment to R&D. The company invests heavily in discovering and developing novel therapies that address significant unmet medical needs, particularly in the areas of rare and complex diseases. Zevra aims to leverage its scientific expertise and innovative technologies to create treatments that improve the quality of life for patients.

2. Partnerships and Collaborations

Zevra recognizes the importance of strategic partnerships in accelerating the development of its products. The company collaborates with academic institutions, research organizations, and other biotechnology firms to enhance its R&D capabilities and bring new therapies to market more efficiently.

3. Regulatory Strategy

Navigating the complex regulatory landscape is crucial for biotechnology companies. Zevra Therapeutics employs a proactive regulatory strategy to ensure that its products meet the necessary safety and efficacy standards set by regulatory authorities. By maintaining open lines of communication with these agencies, Zevra aims to expedite the approval process for its therapies.

4. Commercialization and Market Access

Zevra's commercialization strategy focuses on gaining market access for its therapies once they receive regulatory approval. The company employs a targeted approach to market its products to healthcare providers and patients, emphasizing the unique benefits and value propositions of its therapies.

5. Patient-Centric Approach

Understanding the needs of patients is fundamental to Zevra's business model. The company engages with patient advocacy groups and incorporates patient feedback into its R&D processes to ensure that its therapies are aligned with patient needs and expectations.

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review Zevra Therapeutics, Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

Zevra Therapeutics, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how Zevra Therapeutics, Inc. creates, delivers, and captures value.

Key Partners: Zevra Therapeutics, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Biotechnology sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Zevra Therapeutics, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Zevra Therapeutics, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (59 employees), proprietary technology, and financial resources ($199.51M in cash).

Value Propositions: Zevra Therapeutics, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Biotechnology market.

Customer Relationships: Zevra Therapeutics, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Zevra Therapeutics, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Zevra Therapeutics, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Zevra Therapeutics, Inc.'s major costs include cost of goods sold (19.3% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 84.1% of revenue.

Revenue Streams: Zevra Therapeutics, Inc. generates revenue through its core product and service offerings.

Zevra Therapeutics, Inc. Competitors

Zevra Therapeutics, Inc.'s main competitors include Sarepta Therapeutics, Bluebird Bio, Ultragenyx Pharmaceutical Inc, Amicus Therapeutics, NantKwest. The company operates in the Biotechnology segment of the Healthcare sector where competitive positioning is shaped by product quality, distribution scale, and brand strength.

Competitive Analysis

Zevra Therapeutics, Inc.'s competitive position in Biotechnology is defined by its $494.86M market capitalization and 80.7% gross margins. Key competitive advantages include brand recognition and operational scale in the Biotechnology market.

Zevra Therapeutics, Inc. SWOT Analysis

A SWOT analysis examines Zevra Therapeutics, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Zevra Therapeutics, Inc.'s gross margin of 80.7% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 15.9% demonstrates disciplined cost management even at scale.
• Revenue Growth: Revenue grew 605.4% year-over-year to $84.39M, indicating strong demand for Zevra Therapeutics, Inc.'s products and services and outperformance relative to many industry peers.
• Capital Efficiency: A return on equity of 34.8% demonstrates that Zevra Therapeutics, Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.

Weaknesses

• Competitive Scale Pressure: In the Biotechnology sector, larger competitors with greater economies of scale can exert pricing pressure and outspend Zevra Therapeutics, Inc. on marketing, R&D, and distribution — limiting the company's ability to defend market share in a price-sensitive environment.
• Market Concentration Risk: Revenue concentration in core markets or customer segments creates vulnerability to localized downturns, regulatory changes, or shifts in customer preferences. Diversification remains an ongoing strategic challenge.

Opportunities

• Total Addressable Market: Zevra Therapeutics, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Zevra Therapeutics, Inc.'s products and services.
• Strategic Acquisitions: With $199.51M in cash and strong free cash flow generation, Zevra Therapeutics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Zevra Therapeutics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Zevra Therapeutics, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Zevra Therapeutics, Inc. enters 2026 as a leading company in Healthcare, backed by $84.39 million in annual revenue and a 41.9% net profit margin. The company's 80.7% gross margins and $-30.06 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Zevra Therapeutics, Inc.'s core markets.

For investors, Zevra Therapeutics, Inc.'s 18.7x trailing P/E and 14.2x forward P/E reflect the market's expectations for continued strong growth. Analysts and investors should watch quarterly earnings releases, management commentary on comparable sales growth, margin trends, and capital allocation for signals of how the investment thesis is progressing.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Zevra Therapeutics, SEC EDGAR – Zevra Therapeutics Filings, and Zevra Therapeutics's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. 1. What is Zevra Therapeutics Inc. known for?

Zevra Therapeutics, Inc. generated $84.39 million in annual revenue with a 41.9% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult Zevra Therapeutics, Inc.'s investor relations page.

2. 2. What is the business model of Zevra Therapeutics?

Zevra Therapeutics, Inc. generates $84.39 million in annual revenue (TTM) with a 80.7% gross margin, growing 605.4% year-over-year. The company's revenue model is described in detail in the business model section above.

3. 3. Who are Zevra Therapeutics' main competitors?

Zevra Therapeutics, Inc. competes in the Biotechnology segment of the Healthcare sector. The competitor comparison table in this article outlines key peers by market cap, revenue, and margins. Competitive dynamics in Biotechnology center on product differentiation, pricing strategy, and distribution scale.

4. 4. What are some strengths of Zevra Therapeutics?

Zevra Therapeutics, Inc.'s core strengths include: Zevra Therapeutics, Inc.'s gross margin of 80.7% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 15.9% demonstra Revenue grew 605.4% year-over-year to $84.39M, indicating strong demand for Zevra Therapeutics, Inc.'s products and services and outperformance relative to many industry peers. A return on equity of 34.8% demonstrates that Zevra Therapeutics, Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages. These advantages contribute to the company's durable competitive position in the Biotechnology sector.

5. 5. What challenges does Zevra Therapeutics face?

Zevra Therapeutics, Inc. faces the following external threats: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Zevra Therapeutics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a r Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Zevra Therapeutics, Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri Monitoring these risks is essential for investors tracking the company's long-term trajectory.

6. 6. What opportunities exist for Zevra Therapeutics?

Zevra Therapeutics, Inc.'s key growth opportunities include: Zevra Therapeutics, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this envir Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Zevra T With $199.51M in cash and strong free cash flow generation, Zevra Therapeutics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reac

7. 7. How does Zevra Therapeutics engage with patients?

Zevra Therapeutics, Inc. generates $84.39 million in annual revenue (TTM) with a 80.7% gross margin, growing 605.4% year-over-year. The company's revenue model is described in detail in the business model section above.